Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cell Death and Differentiation|June 11, 2005
MIF loss impairs Myc-induced lymphomagenesisF Talos, P Mena, G Fingerle-Rowson, et al.
Clinical and Experimental Immunology|July 2, 1998
Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapyG Fingerle-Rowson, M Angstwurm, R Andreesen, et al.
Shock (Augusta, Ga.)|July 1, 1997
Cytokine production precedes the expansion of CD14+CD16+ monocytes in human sepsis: a case report of a patient with self-induced septicemiaM Blumenstein, P Boekstegers, P Fraunberger, et al.
Inflammation|July 24, 1998
Expansion of CD14+CD16+ monocytes in critically ill cardiac surgery patientsG Fingerle-Rowson, J Auers, E Kreuzer, et al.
International Journal of Hematology|May 10, 2011
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myelomaStefan Schmitt, H Goldschmidt, B Storch-Hagenlocher, et al.
The Journal of Thoracic and Cardiovascular Surgery|May 30, 1998
Down-regulation of surface monocyte lipopolysaccharide-receptor CD14 in patients on cardiopulmonary bypass undergoing aorta-coronary bypass operationG Fingerle-Rowson, J Auers, E Kreuzer, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2003
The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targetingG Fingerle-Rowson, O Petrenko, C N Metz, et al.
Oncogene|February 22, 2007
Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activityH Lue, M Thiele, J Franz, et al.
Leukemia|July 31, 2009
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysisS Böttcher, S Stilgenbauer, R Busch, et al.
Leukemia|April 9, 2004
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)C-M Wendtner, M Ritgen, C D Schweighofer, et al.
Pageof 2